Back to Top Skip to main content Skip to sub-navigation

Incident COVID-19 Infections, Active and Reserve Components, Jan. 1, 2020–Aug. 31, 2021

Image of U.S. Marines with Marine Rotational Force - Darwin receive a second COVID-19 test during quarantine on Royal Australian Air Force Base Darwin in Darwin, NT, Australia, June 12, 2020. The COVID-19 test was administered to each Marine after arriving from California. All Marines will be quarantined for 14 days and undergo an additional test before quarantine release. No Marines tested positive for COVID-19. The U.S. Marine Corps and Australian Defence Force service members are working together to ensure the safety of the local community. (U.S. Marine Corps photo by Lance Cpl. Natalie Greenwood). U.S. Marines with Marine Rotational Force - Darwin receive a second COVID-19 test during quarantine on Royal Australian Air Force Base Darwin in Darwin, NT, Australia, June 12, 2020. The COVID-19 test was administered to each Marine after arriving from California. All Marines will be quarantined for 14 days and undergo an additional test before quarantine release. No Marines tested positive for COVID-19. The U.S. Marine Corps and Australian Defence Force service members are working together to ensure the safety of the local community. (U.S. Marine Corps photo by Lance Cpl. Natalie Greenwood)

Recommended Content:

Medical Surveillance Monthly Report

What are the New findings?

This study describes the characteristics of COVID-19 cases among U.S. service members to date, including the prevalence of pre-existing comorbidities, vaccination status, and the proportion of cases hospitalized. This report also describes the characteristics of service members who died from COVID-19 during the surveillance period.

What is the Impact on Readiness and Force Health Protection?

Detailed data on demographic characteristics, underlying medical conditions, and vaccination status can inform targeted communication to encourage persons in at-risk groups to practice preventive measures and promptly seek medical care if they become ill. Enhanced surveillance efforts can enable actions to prevent and control the current COVID-19 epidemic, which threatens the health of the force.

Abstract

Between Jan. 1, 2020 and Aug. 31, 2021, a total of 189,239 service members were identified as confirmed or probable cases of COVID-19. The majority of cases were male (81.2%) and 57.3% were aged 20–29 years. Overall, 19.2% had a diagnosis of at least 1 of the pre-existing comorbidities of interest in the year prior to becoming a case. The most common pre-existing comorbidity was obesity or overweight (5.2%), followed by cardiovascular disease (4.2%), and substance use disorder including nicotine dependence (4.0%). Service members who were hospitalized for COVID-19 were twice as likely to have a diagnosis of any pre-existing comorbidity compared to those who were not hospitalized. There were a total of 1,760 hospitalizations (0.9%) and 45 deaths reported among service members. In addition, there were 11,899 cases observed among fully vaccinated individuals; however, only 0.4% of hospitalized cases were fully vaccinated and no service member deaths occurred among fully vaccinated individuals during the surveillance period, highlighting the importance of COVID-19 vaccination for force health protection.

Background

Since the beginning of the COVID-19 pandemic, there have been over 249 million COVID-19 cases and 5 million COVID-related deaths worldwide, including over 46 million cases and over 754 thousand deaths in the U.S.1 Although most symptomatic cases of COVID-19 are mild, severe disease occurs in any demographic group.2,3 Older individuals and those with underlying medical conditions are at higher risk of serious illness and death; this risk increases with advancing age.3 The majority of COVID-19 deaths occur among adults aged 60 or older and among persons with serious underlying health conditions such as cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), heart conditions (e.g., heart failure, coronary artery disease, cardiomyopathies), an immunocompromised state from solid organ transplant, and obesity (body mass index [BMI]=30–39.9 kg/m2).4,5

Two mRNA vaccines for COVID-19 (Moderna and Pfizer-BioNTech) were approved in December 2020 and an adenovirus-vectored vaccine (Janssen) was approved in late February 2021. Randomized clinical trials have shown that the current mRNA-based COVID-19 vaccines have high efficacies (94%–95%) for preventing COVID-19.6,7 The Janssen adenovirus vectored vaccine also had moderately high efficacy against symptomatic COVID-19 (66%) and high efficacy against hospitalization for COVID-19 (93%).8,9 Since these vaccines became available and used in the U.S., they have had substantial impacts on mitigating COVID-19 outbreaks and reducing risk of hospitalization and death.10 Concerns were initially raised about the effectiveness of these vaccines against emerging new strains of SARS-CoV-2, including the Delta (B.1.617.2) variant, which became the predominant variant of the virus in the U.S. in July 2021.12 There is currently very limited information about real-world effectiveness of the Janssen vaccine against the Delta variant. However, several studies have indicated moderate to high effectiveness of the Moderna and Pfizer-BioNTech vaccines against the Delta variant, particularly for preventing hospitalization and death.12–14

The Department of Defense (DOD) began COVID-19 vaccination in mid-December 2020. These vaccines were originally made available to service members on a voluntary basis according to occupational risk, but were made mandatory on 24 August 2021.15 The objective of this study was to provide an update on the numbers of probable and confirmed COVID-19 cases among U.S. military service members in addition to describing demographics, prevalence of pre-existing comorbidities, hospitalization rates, and deaths.

Methods

Since March 2020, the Armed Forces Health Surveillance Division (AFHSD) has maintained a case list of MHS beneficiaries with COVID-19. This list is updated daily and comprises Composite Health Care System (CHCS) Health Level 7 (HL7)-formatted and MHS Genesis laboratory positive test results extracted by the Navy and Marine Corps Public Health Center Epi Data Center (for all services), as well as medical event reports of laboratory confirmed and probable COVID-19 infection derived from the Disease Reporting System Internet (DRSi). AFHSD also maintains the Defense Medical Surveillance System (DMSS), a continuously expanding relational database of personnel and medical data.

For this analysis, cases of COVID-19 among active and reserve/guard component service members were included if the incident date occurred within 90 days of a personnel demographic record maintained in the DMSS. Beneficiary status (i.e., active or reserve/guard component) and branch of military service were determined based on the information recorded in the DMSS. The incident date for each COVID-19 case was defined as the earliest date of onset recorded in the DRSi, or the earliest collection date for the sample that tested positive via PCR or antigen laboratory testing.

In addition, DMSS data were used to identify hospitalizations for COVID-19 and for demographic information that was missing from the case list. DMSS data were also used to identify comorbidities from administrative records of inpatient and outpatient medical encounters, which included encounters from fixed military treatment facilities as well as outsourced care reimbursed by TRICARE. A hospitalization for COVID-19 was defined by having an inpatient record in DMSS occurring within 30 days after the first case record for COVID-19, with the International Classification of Diseases, 10th Revision (ICD-10) code U07.1 in the first or second diagnostic position, or a diagnosis of COVID-like illness in the first or second diagnostic position (Table 1). An individual was considered to have a pre-existing comorbidity if there was an inpatient or outpatient encounter record containing an ICD-10 code for a comorbidity of interest within 365 days prior to the COVID-19 incident date (Table 2). 

Data on vaccination status at the time of the incident COVID-19 infection were derived from immunization records in the DMSS. An individual was considered fully vaccinated at the time of the case if the incident date occurred at least 14 days after the second dose of the Moderna (vaccine administered [CVX] code=207) or Pfizer-BioNTech (CVX code=208) vaccine, or at least 14 days after the first dose of the Janssen vaccine (CVX code=212). An individual was considered partially vaccinated if the individual had received at least 1 dose of vaccine but did not meet the aforementioned 14-day criteria for full vaccination. 

COVID-19-related deaths occurring among service members were tracked and reported separately from cases of COVID-19. These deaths were identified via communication with the Armed Forces Medical Examiner System and via media reports, Director's Critical Information Requirement reports, the DRSi, and chart review of service members' electronic health record in the Armed Forces Health Longitudinal Technology Application (AHLTA). Information documented in these sources were used to describe pre-existing comorbidities and clinical course among those who died from COVID-19.

Results

As of Aug. 31, 2021, a total of 189,239 service members were identified as confirmed or probable cases of COVID-19 (Table 3). Of these cases, 19.2% had a medical encounter for at least 1 of the pre-existing comorbidities of interest in the year prior to becoming a case, and 6.9% had an encounter for 2 or more pre-existing comorbidities. There were a total of 1,760 hospitalizations (0.9%) and 45 deaths. Of the 42 deaths with past medical history data available for review, 17 (40.5%) had 1 pre-existing comorbidity of interest, 15 (35.7%) had 2 or more comorbidities and 10 (23.8%) had no comorbidities. A total of 111,801 cases occurred after COVID-19 vaccinations became available to the DOD on 11 December 2020. Among these cases, 83.7% (n=93,616) occurred among unvaccinated service members, 10.6% (n=11,899) cases occurred among fully vaccinated individuals, and 5.6% (n=6,286) occurred among partially vaccinated individuals. A total of 48 hospitalizations for COVID-19 occurred among fully vaccinated service members and there were 44 hospitalizations among partially vaccinated service members (data not shown). No service member deaths occurred among vaccinated individuals, except for 1 active duty member who had received 1 dose of Pfizer vaccine 18 days prior to his death.

Service members who were hospitalized for COVID-19 were twice as likely to have a diagnosis of any comorbidity in the year prior to becoming a case compared to those who were not hospitalized, and almost 3 times as likely to have a diagnosis of multiple comorbidities (Table 4). Of note, those who were hospitalized were 5 times as likely to have a prior diagnosis of chronic liver disease and almost 4 times as likely to have a prior hypertension diagnosis, compared to those who were not hospitalized. Of the 32 service member deaths with hospitalization data available, 24 (75.0%) were hospitalized at the time of death, 8 (25.0%) were found unresponsive at home or at an alternate site, and 1 died en route to the hospital.

The highest peak in the number of past 14-day incident COVID-19 cases among all service members occurred on Jan. 15, 2021 with a total of 16,418 past 14-day cases, and was preceded by a peak on Dec. 11, 2020 of 11,131 past 14-day cases (Figure). Following the peak on Jan. 15, 2021, there was another peak on Aug. 25, 2021 of 9,875 past 14-day cases coinciding with the period of transmission of the Delta variant.

Active component

A total of 163,171 active component members had been infected with the SARS-CoV-2 virus as of 31 August 2021 (Table 3). The largest demographic proportions of cases were among those who were male (81.6%), aged 20–24 (37.5%), non-Hispanic White (51.0%), and in the Army (42.0%). About one-fifth (19.9%) of the infected cases had a diagnosis of a pre-existing comorbidity in the year prior to becoming a case, and 7.0% were diagnosed with 2 or more comorbidities. Of the comorbidities that were assessed, the most commonly diagnosed were obesity or overweight (n= 8,690; 5.3%), substance use including nicotine dependence (n= 7,191; 4.4%), and cardiovascular disease (n= 6,840; 4.2%). A total of 1,504 active component members (0.9%) were hospitalized, with a median hospital stay of 4 days (interquartile range [IQR]=2–6). A total of 10,731 cases (11.1%) among the 96,539 cases that occurred after Dec. 11, 2020 were fully vaccinated, and 5.6% (n=5,396) were partially vaccinated.

During the surveillance period, there were 17 deaths among active component COVID-19 cases (data not shown). Past medical history was available in AHLTA for all of the active component service member deaths reviewed. COVID-specific case-related information, including clinical progression of illness, was available for review in 12 (70.6%) AHLTA records and 17 (100.0%) corroborative clinical reports and summaries, typically prepared by the services following a death. Of the active component deaths, 7 (41%) were Army, 7 (41%) were Navy, 2 (12%) were Air Force, and 1 (6%) was Marine Corps. The average age at death was 39 years. A majority (82.4%; n=14) of those who died had at least 1 comorbidity of interest and 52.9% (n=9) had a BMI that placed them in the overweight or obese category. The 2 most common pre-existing comorbidities among those who died were obesity (52.9%; n=9) and cardiovascular disease, primarily hyperlipidemia (23.5%, n=4). At the time of death, 11 service members were hospitalized, 4 were "found unresponsive" at home or at an alternative site and later pronounced dead in the emergency room, and 1 died en route to the hospital. Hospitalization data for 1 service member was not available. The clinical progression of illness for most hospitalized cases followed a standard pattern of deterioration: onset of symptomatic illness, increasing dyspnea (shortness of breath) with development of COVID pneumonia, ICU admission; onset of acute respiratory distress syndrome (ARDS) followed by intubation and mechanical ventilation, development of COVID-related complications (e.g., cardiogenic shock, myocarditis, deep vein thrombosis, disseminated intravascular coagulation, etc.) and death. None of the active component service members who died were fully vaccinated.

Reserve/Guard component

A total of 26,068 COVID-19 cases were identified among reserve and guard service members (Table 3). The largest proportions of cases were male (79.1%), aged 20–24 (21.5%), non-Hispanic White (55.7%), and in the Army (68.9%). About one-seventh (14.3%) of cases were diagnosed with a pre-existing comorbidity, and 6.5% were diagnosed with 2 or more comorbidities. Of the pre-existing comorbidities that were assessed, the most commonly diagnosed comorbidities were obesity or overweight (n=1,104; 4.2%), cardiovascular disease (n=1,079; 4.1%), and neoplasms (n=884; 3.4%). A total of 256 reserve/guard members (1.0%) were hospitalized, with a median hospital stay of 4 days (IQR=2.5–7). A total of 1,168 cases (7.7%) among the 15,262 cases that occurred after Dec. 11, 2020 were fully vaccinated, and 5.8% (n=890) were partially vaccinated.

There were 28 deaths among reserve and guard COVID-19 cases; of these, 8 were on active duty status at the time of death (data not shown). Past medical history was available in AHLTA for 25 (89.3%) of the reserve/guard deaths reviewed. COVID-specific case-related information, including clinical progression of illness, was available in AHLTA and corroborative clinical reports/summaries for all of the reserve/guard members who died while on active duty, but only available for 5 (25%) reserve/guard members who died while not on active duty. Similarly, vaccination status was available for all of the activated reserve/guard members who died, but only available for 11 (55%) of the inactivated reserve/guard members who died. Of the total reserve guard deaths, 19 (67.9%) were Army, 5 (17.9%) were Navy, and 4 (14.3%) were Air Force. The average age at death was 47 years. Of those with available data in AHLTA or in other sources, 15 (62.2%; 15/23) had at least 1 pre-existing comorbidity and 12 (54.5%; 12/22) had BMIs that placed them in the category of overweight or obese. Similar to the active component, the most common comorbidities among reserve/guard deaths were obesity (54.5%) and cardiovascular disease (25.0%; 6/24), with 4 having a diagnosis of hyperlipidemia. Of the 11 inactive reserve/guard service members with available COVID-specific case-related data, 8 (72.7%) were hospitalized at the time of death with a clinical progression of illness that followed the standard pattern outlined above and 3 (27.3%) were found unresponsive at home or at an alternate site and later pronounced dead in the emergency room. None of the reserve/guard service members who died were fully vaccinated.

Editorial Comment

This report describes the demographic characteristics and prevalence of pre-existing comorbidities among service members with incident COVID-19 infection. Not surprisingly, cases among service members (including recruits) were most commonly diagnosed in young, non-Hispanic White males, which follows the expected demographic distributions of these groups. Overall, 19.2% had a medical encounter for at least 1 of the pre-existing comorbidities of interest in the year prior to becoming a case. The most common pre-existing comorbidities in both hospitalized and non-hospitalized cases were obesity or overweight, followed by cardiovascular disease. These same pre-existing comorbidities were also common among service members who died from COVID-19.

For each of the comorbidities evaluated in this study, hospitalized COVID-19 cases were more likely than non-hospitalized cases to have had a medical encounter for the condition in the past year. Chronic liver disease, hypertension, and chronic kidney disease were among the comorbidities most likely to be previously diagnosed in the hospitalized cases compared to the non-hospitalized cases. The finding that chronic liver disease was more likely to be diagnosed in hospitalized compared to non-hospitalized cases is noteworthy because recent studies have suggested that chronic liver disease is not a significant comorbid condition for COVID-19.16,17 However, other studies have indicated that cirrhosis increases risk for COVID-19 hospitalization and death among patients with chronic liver disease, and that cirrhosis may play a role in immune dysfunction.18,19

There were totals of 1,760 hospitalizations (0.9%) and 45 deaths among service members as of Aug. 31, 2021. Although there were 11,899 cases of COVID-19 occurring among fully vaccinated individuals, only 0.4% of hospitalized cases were fully vaccinated and no service member deaths occurred among fully vaccinated individuals, highlighting the importance of COVID-19 vaccination for force health protection. In particular, 45 deaths corresponds to a cumulative case fatality ratio of about 0.02% (i.e., 1 death per 4,205 infected), which is much lower than the case fatality ratio of 1.6% observed in the general U.S. population.20 This lower case fatality ratio is not surprising given that service members are on average younger and healthier compared to members of the general U.S. population. 

It should be noted that the progression of illness followed a standard clinical course for a majority of service members who died from COVID-19 during the surveillance period.21 However, there were a few individuals who experienced rapid deterioration after having been discharged from the hospital and some who died suddenly at home or at an alternate site with COVID symptoms or a previously diagnosed COVID-19 infection. Acute respiratory and thrombotic complications of COVID-19 have been previously reported as common causes of death, with many patients having comorbidities such as hypertension, ischemic heart disease, and obesity.22 In patients who die suddenly, severe systemic inflammation, multi-organ dysfunction, and cardiovascular failure may also play a role.23–25 It is important to note that, although service members are a generally young and healthy population experiencing few deaths due to COVID-19, they are still vulnerable to the harmful effects of this disease particularly if they have pre-existing comorbidities and are unvaccinated.

There are several limitations that should be considered when interpreting the results of this study. First, the prevalence of pre-existing comorbidities among all cases may be underestimated because medical encounter data were queried in the year prior to the incident date of the case. Individuals who did not seek medical care for these conditions during this time period would not be captured. However, comorbidities may also be overestimated because the case definition allowed for only a single medical encounter to qualify as a comorbidity; therefore, screening encounters that were miscoded using the diagnosis code for that condition may overestimate the occurrence of certain pre-existing comorbidities. Importantly, as the science evolves more is being learned about the types of medical conditions that place individuals at higher risk for severe illness from COVID-19. The list of comorbidities investigated in this analysis is not exhaustive and should be re-evaluated in subsequent investigations. Second, the expansion of MHS Genesis to military treatment facilities throughout most of the western U.S. presented challenges to linking MHS GENESIS laboratory records with case information in the DRSi and the CHCS. As a result, some cases may have been missed. Finally, the number of cases, vaccination information, and hospitalization status may have also been underestimated if individuals were seen for care outside of the MHS TRICARE network, which is most likely to occur among inactivated reserve/guard members.

The COVID-19 pandemic continues to have persistent person-to-person spread in the community worldwide and will require continuous monitoring as new variants of the SARS-CoV-2 virus emerge. Findings presented here draw attention to the necessity of building on present-day disease surveillance efforts to collect and analyze case prevalence data, and in particular data including vaccination status, hospitalization, death, and serious underlying health conditions. Continued surveillance of COVID-19 among service members remains an important part of force health protection efforts.

References

1. Johns Hopkins University Coronavirus Resource Center. Mortality Analyses. Updated 6 November 2021. Accessed 6 November 2021. https://coronavirus.jhu.edu/map.html

2. The Novel Coronavirus Pneumonia Emergency Response Epidemiology. The Epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. China CDC Weekly. 2020;2(8):113–122.

3. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—U.S., February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343–346.

4. Centers for Disease Control and Prevention. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—U.S., February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382–386.

5. Centers for Disease Control and Prevention. People who are at increased risk for severe illness with certain medical conditions. Accessed 11 November 2021. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html

6. Polack FP, Thomas SJ, Kitchen N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.

7. Baden LR El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–416.

8. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201.

9. Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunizations Practises’ interim recommendation for use of the Janssen COVID-19 vaccine – United States, February 2021. MMWR. 2021;70(9):329–332.

10. Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on COVID-19 outbreaks in the United States. Clin Infect Dis. 2021;ciab079.

11. Centers for Disease Control and Prevention. Delta Variant: What We Know About the Science. Accessed 11 November 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html.

12. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;s41591-021-01583-4.

13. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585–594. 

14. Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1156–1162.

15. Department of Defense. Deputy Secretary of Defense. Memo: Mandatory coronavirus disease 2019 vaccination of Department of Defense service members. 21 August 2021. Accessed 11 November 2021. https://media.defense.gov/2020/Dec/08/2002548508/-1/-1/0/CORONAVIRUS-DISEASE-2019-VACCINE-GUIDANCE.PDF

16. Lippi G, de Oliveira MHS, Henry BM. Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): A pooled analysis. Eur J Gastroenterol Hepatol. 2021;33(1):114–115.

17. Lin, J., Bao, B., Khurram, N.A. et al. Chronic liver disease not a significant comorbid condition for COVID-19. Sci Rep. 2021;11(1):11734.

18. Sharma P, Kumar A, Anikhindi S, et al. Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know? J Clin Exp Hepatol. 2021;11(4):484–493. 

19. Marjot T, Webb GJ, Barritt AS 4th, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348–364. 

20. Johns Hopkins University Coronavirus Resource Center. Mortality Analyses. Updated 11 November 2021. Accessed 11 November 2021. https://coronavirus.jhu.edu/data/mortality

21. Cates J, Lucero-Obusan C, Dahl RM, et al. Risk for In-Hospital Complications Associated with COVID-19 and Influenza - Veterans Health Administration, United States, October 1, 2018-May 31, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(42):1528–1534.  

22. Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11(1):4263. 

23. Yang N, Tian K, Jin M, et al. Sudden death of COVID-19 patients in Wuhan, China: A retrospective cohort study. J Glob Health. 2021;11:05006. 

24. Polat V, Bostancı Gİ. Sudden death due to acute pulmonary embolism in a young woman with COVID-19. J Thromb Thrombolysis. 2020;50(1):239–241. 

25. Giudicessi JR. Excess out-of-hospital sudden deaths during the COVID-19 pandemic: A direct or indirect effect of SARS-CoV-2 infections? Heart Rhythm. 2021;18(2):219–220.

FIGURE. Past 14-day COVID-19 cases, active and reserve components, U.S. Armed Forces, 1 January 2020–31 August 2021

 

TABLE 1. ICD-10 codes used to identify hospitalizations for COVID-19

TABLE 2. ICD-10 codes used to identify comorbidities

TABLE 3. COVID-19 confirmed and probable cases, active and reserve components, U.S. Armed Forces, 1 January 2020–31 August 2021

TABLE 3 (cont) . COVID-19 confirmed and probable cases, active and reserve components, U.S. Armed Forces, 1 January 2020–31 August 2021

TABLE 4. Pre-existing comorbidities by hospitalization status, active and reserve components, U.S. Armed Forces, 1 January 2020–31 August 2021

You also may be interested in...

MSMR Vol. 29 No. 07 - July 2022

Report
7/1/2022

A monthly publication of the Armed Forces Health Surveillance Division. This issue of the peer-reviewed journal contains the following articles: Surveillance trends for SARS-CoV-2 and other respiratory pathogens among U.S. Military Health System Beneficiaries, Sept. 27, 2020 – Oct. 2,2021; Establishment of SARS-CoV-2 genomic surveillance within the MHS during March 1 – Dec. 31 2020; Suicide behavior among heterosexual, lesbian/gay, and bisexual active component service members in the U.S. Armed Forces; Brief report: Phase I results using the Virtual Pooled Registry Cancer Linkage system (VPR-CLS) for military cancer surveillance.

Recommended Content:

Health Readiness & Combat Support | Public Health | Medical Surveillance Monthly Report

Absolute and Relative Morbidity Burdens Attributable to Various Illnesses and Injuries, Non-service Member Beneficiaries of the Military Health System, 2021

Article
6/1/2022

In 2021, mental health disorders accounted for the largest proportions of the morbidity and health care burdens that affected the pediatric and younger adult beneficiary age groups. Among adults aged 45–64 and those aged 65 or older, musculoskeletal diseases accounted for the most morbidity and health care burdens. As in previous years, this report documents a substantial majority of non-service member beneficiaries received care for current illness and injury from the Military Health System as outsourced services at non-military medical facilities.

Recommended Content:

Medical Surveillance Monthly Report

Surveillance snapshot: Illness and injury burdens, reserve component, U.S. Armed Forces, 2021

Article
6/1/2022
Surveillance snapshot: Illness and injury burdens, reserve component, U.S. Armed Forces, 2021

Recommended Content:

Medical Surveillance Monthly Report

Morbidity Burdens Attributable to Various Illnesses and Injuries, Deployed Active and Reserve Component Service Members, U.S. Armed Forces, 2021

Article
6/1/2022

As in previous years, among service members deployed during 2021, injury/poisoning, musculoskeletal diseases and signs/symptoms accounted for more than half of the total health care burden during deployment. Compared to garrison disease burden, deployed service members had relatively higher proportions of encounters for respiratory infections, skin diseases, and infectious and parasitic diseases. The recent marked increase in the percentage of total medical encounters attributable to the ICD diagnostic category "other" (23.0% in 2017 to 44.4% in 2021) is likely due to increases in diagnostic testing and immunization associated with the response to the COVID-19 pandemic.

Recommended Content:

Medical Surveillance Monthly Report

Medical Evacuations out of the U.S. Central and U.S. Africa Commands, Active and Reserve Components, U.S. Armed Forces, 2021

Article
6/1/2022
Medical Evacuations out of the U.S. Central and U.S. Africa Commands, Active and Reserve Components, U.S. Armed Forces, 2021

The proportions of evacuations out of USCENTCOM that were due to battle injuries declined substantially in 2021. For USCENTCOM, evacuations for mental health disorders were the most common, followed by non-battle injury and poisoning, and signs, symptoms, and ill-defined conditions. For USAFRICOM, evacuations for non-battle injury and poisoning were most common, followed by disorders of the digestive system and mental health disorders.

Recommended Content:

Medical Surveillance Monthly Report

Ambulatory Visits, Active Component, U.S. Armed Forces, 2021

Article
6/1/2022

In 2021, the overall numbers and rates of active component service member ambulatory care visits were the highest of any of the last 10 years. Most categories of illness and injury showed modest increases in numbers and rates. The proportions of ambulatory care visits that were accomplished via telehealth encounters fell to under 15% in 2021, compared to 19% in 2020.

Recommended Content:

Medical Surveillance Monthly Report

Hospitalizations, Active Component, U.S. Armed Forces, 2021

Article
6/1/2022

The hospitalization rate in 2021 was 48.0 per 1,000 person-years (p-yrs), the second lowest rate of the most recent 10 years. For hospitalizations limited to military facilities, the rate in 2021 was the lowest for the entire period. As in prior years, the majority (71.2%) of hospitalizations were associated with diagnoses in the categories of mental health disorders, pregnancy-related conditions, injury/poisoning, and digestive system disorders.

Recommended Content:

Medical Surveillance Monthly Report

Absolute and Relative Morbidity Burdens Attributable to Various Illnesses and Injuries, Active Component, U.S. Armed Forces, 2021

Article
6/1/2022

In 2021, as in prior years, the medical conditions associated with the most medical encounters, the largest number of affected service members, and the greatest number of hospital days were in the major categories of injuries, musculoskeletal disorders, and mental health disorders. Despite the pandemic, COVID-19 accounted for less than 2% of total medical encounters and bed days in active component service members.

Recommended Content:

Medical Surveillance Monthly Report

Surveillance Snapshot: Tick-borne Encephalitis in Military Health System Beneficiaries, 2012–2021

Article
5/1/2022
iStock—The castor bean tick (Ixoedes ricinus). Credit: Erik Karits

Tick-borne Encephalitis in Military Health System Beneficiaries, 2012–2021. Tick-borne encephalitis (TBE) is a viral infection of the central nervous system that is transmitted by the bite of infected ticks, mostly found in wooded habitats in parts of Europe and Asia

Recommended Content:

Medical Surveillance Monthly Report

Evaluation of ICD-10-CM-based Case Definitions of Ambulatory Encounters for COVID-19 Among Department of Defense Health Care Beneficiaries

Article
5/1/2022
SEATTLE, WA, UNITED STATES 04.05.2020 U.S. Army Maj. Neil Alcaria is screened at the Seattle Event Center in Wash., April 5. Soldiers from Fort Carson, Colo., and Joint Base Lewis-McChord, Wash. have established an Army field hospital center at the center in support of the Department of Defense COVID-19 response. U.S. Northern Command, through U.S. Army North, is providing military support to the Federal Emergency Management Agency to help communities in need. (U.S. Army photo by Cpl. Rachel Thicklin)

This is the first evaluation of ICD-10-CM-based cased definitions for COVID-19 surveillance among DOD health care beneficiaries. The 3 case definitions ranged from highly specific to a lower specificity, but improved balance between sensitivity and specificity.

Recommended Content:

Medical Surveillance Monthly Report

Update: Sexually Transmitted Infections, Active Component, U.S. Armed Forces, 2013–2021

Article
5/1/2022
This illustration depicts a 3D computer-generated image of a number of drug-resistant Neisseria gonorrhoeae bacteria. CDC/James Archer

This report summarizes incidence rates of the 5 most common sexually transmitted infections (STIs) among active component service members of the U.S. Armed Forces during 2013–2021. In general, compared to their respective counterparts, younger service members, non-Hispanic Black service members, those who were single and other/unknown marital status, and enlisted service members had higher incidence rates of STIs.

Recommended Content:

Medical Surveillance Monthly Report

The Association Between Two Bogus Items, Demographics, and Military Characteristics in a 2019 Cross-sectional Survey of U.S. Army Soldiers

Article
5/1/2022
NIANTIC, CT, UNITED STATES 06.16.2022 U.S. Army Staff Sgt. John Young, an information technology specialist assigned to Joint Forces Headquarters, Connecticut Army National Guard, works on a computer at Camp Nett, Niantic, Connecticut, June 16, 2022. Young provided threat intelligence to cyber analysts that were part of his "Blue Team" during Cyber Yankee, a cyber training exercise meant to simulate a real world environment to train mission essential tasks for cyber professionals. (U.S. Army photo by Sgt. Matthew Lucibello)

Data from surveys may be used to make public health decisions at both the installation and the Department of the Army level. This study demonstrates that a vast majority of soldiers were likely sufficiently engaged and answered both bogus items correctly. Future surveys should continue to investigate careless responding to ensure data quality in military populations.

Recommended Content:

Medical Surveillance Monthly Report

Exertional Heat Illness at Fort Benning, GA: Unique Insights from the Army Heat Center

Article
4/1/2022
Navy Petty Officer 3rd Class Ryan Adams is being used as an example victim for cooling a heat casualty at the bi-annual hot weather standard operating procedure training aboard Marine Corps Base Camp Lejeune, N.C., Aug. 24. Adams is demonstrating the "burrito" method used to cool a heat related injury victim. Photo by Pfc. Joshua Grant.

Exertional heat illness (hereafter referred to as heat illness) spans a spectrum from relatively mild conditions such as heat cramps and heat exhaustion, to more serious and potentially life-threatening conditions such as heat injury and exertional heat stroke (hereafter heat stroke).

Recommended Content:

Medical Surveillance Monthly Report

Exertional Rhabdomyolysis, Active Component, U.S. Armed Forces, 2017–2021

Article
4/1/2022
The Embry-Riddle Army ROTC Ranger Challenge team heads out on the 12-mile road march after completing the timed obstacle course event of the 6th Brigade Army ROTC Ranger Challenge January 14, 2022 at Fort Benning, Ga. The Titan Brigade’s Ranger Challenge took place at Fort Benning, Ga. January 13-15, 2022. Photo by Capt. Stephanie Snyder

Exertional rhabdomyolysis is a potentially serious condition that requires a vigilant and aggressive approach. Some service members who experience exertional rhabdomyolysis may be at risk for recurrences, which may limit their military effectiveness and potentially predispose them to serious injury.

Recommended Content:

Medical Surveillance Monthly Report

Heat Illness, Active Component, U.S. Armed Forces, 2021

Article
4/1/2022
Airmen participate in the 13th Annual Fallen Defender Ruck March at Joint Base San Antonio, Nov. 6, 2020. The event honors 186 fallen security forces, security police and air police members who have made the ultimate sacrifice. Photo By: Sarayuth Pinthong, Air Force.

From 2020 to 2021, the rate of incident heat stroke was relatively stable while the rate of heat exhaustion increased slightly

Recommended Content:

Medical Surveillance Monthly Report
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 13
Refine your search
Last Updated: August 16, 2022

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.